and was cost-effective. 2 However, the addition of concurrent chemotherapy to radiotherapy is often contraindicated due to comorbidity and has not been found to be beneficial to patients with stage I/II disease, age ≥70 years old, WHO performance status ≥2. 4 There is a paucity of data to determine whether response assessment PET-CT after radiotherapy alone is sufficiently accurate to influence management.
| Response assessment
Tumour response was routinely assessed 4 months after the completion of radiotherapy by clinical examination and FDG PET-CT (according to previously described imaging protocols 3, 5 ). Planned neck dissections were not performed.
| Categorisation of FDG PET-CT response assessment
Categorisation of FDG PET-CT response was based upon radiology reports as previously described. 3, 5 Results of post-treatment FDG PET-CT were qualitatively categorised into "complete,"
"equivocal" or "incomplete" for the primary site and nodal sites separately. A complete response was defined as the absence of any abnormal focal FDG uptake or diffuse FDG uptake in the absence of corresponding anatomical abnormality on the CT which was considered to be radiotherapy related. An incomplete response was defined as focal uptake, corresponding to a structural abnormality and of greater intensity than background liver activity. Scans were classed as equivocal if focal FDG uptake was below liver background but above that of surrounding normal tissues.
Keypoints
• FDG PET-CT is an established tool for response assessment following definitive concurrent chemoradiotherapy for head and neck squamous cell carcinoma with a high negative predictive value guiding treatment decisions.
• Little data are available regarding the accuracy of FDG PET-CT for response assessment following definitive radiotherapy without chemotherapy.
• We retrospectively analysed the accuracy of FDG PET-CT for response assessment following radiotherapy alone without planned neck dissection in 45 patients.
• PET-CT had a high negative predictive value of 93% and positive predictive value of 88%.
• Based upon the high negative predictive value, PET-CT can be used to avoid surgical intervention following radiotherapy alone. 
| Analysis and statistics
Duration of follow-up was defined from final day of radiotherapy. Sensitivity, specificity, positive predictive value (PPV) and NPV were calculated using 2 9 2 tables constructed using clinico-pathological outcomes.
| RESULTS
Median follow-up for living patients was 32 months (range 8-65).
Median age was 68 years (range 40-83); 32 of 45 (71%) were male.
Disease and treatment characteristics are shown in Table 1 Table 2 demonstrates the sensitivity, specificity, PPV and NPV for the response assessment FDG PET-CT outcomes. Where primary tumour or lymph nodes were not assessable on the baseline FDG PET-CT, these were omitted from the analysis of the respective response assessments.
With regard to the primary site, a complete metabolic response was demonstrated in 27 of 36 (75%) patients with an FDG-avid primary site at baseline assessment; NPV was 92%. 
| DISCUSSION
The accuracy of a test depends upon the population to which it is applied, and the accuracy of PET-CT for response assessment may vary depending upon treatment strategy. To guide a surveillance strategy following radiotherapy alone, which is a less intensive treatment than chemoradiotherapy, it is essential to determine whether the NPV of FDG PET-CT is high with regard to both primary and nodal diseases.
| Synopsis of key findings
In this series of 45 patients, the NPV of a complete metabolic response of PET-CT was high, 92%, 95% and 93% for the primary site, lymph nodes and overall, respectively. The PET-CT response scan was false negative in 2 of 45 (4%) patients. The PPV of incomplete response or equivocal FDG uptake grouped together was high, 80%, 91% and 88% for primary site, lymph nodes and overall, respectively. Overall sensitivity and specificity were high (88% and 93%, respectively). Despite the use of PET-CT for staging pretreatment, 18% of patients were found to have developed distant metastatic disease on response assessment PET-CT.
| Study limitations
Limitations include the retrospective nature of the analysis, along with the limited size of study population. Few patients had an equivocal response, precluding conclusions regarding optimal management of this subgroup. Human papilloma virus testing was not routinely available for patients treated in this era.
| Comparison with other studies

